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Abstract: Importance: A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral
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within-couple HIV transmission (heterosexual and men who have sex with men [MSM]) during periods of
sex without condoms and when the HIV-positive partner had HIV-1 RNA load less than 200 copies/mL.
Design, Setting, and Participants: The prospective, observational PARTNER (Partners of People on
ART—A New Evaluation of the Risks) study was conducted at 75 clinical sites in 14 European countries
and enrolled 1166 HIV serodifferent couples (HIV-positive partner taking suppressive ART) who reported
condomless sex (September 2010 to May 2014). Eligibility criteria for inclusion of couple-years of follow-
up were condomless sex and HIV-1 RNA load less than 200 copies/mL. Anonymized phylogenetic analysis
compared couples’ HIV-1 polymerase and envelope sequences if an HIV-negative partner became infected
to determine phylogenetically linked transmissions. Exposures: Condomless sexual activity with an HIV-
positive partner taking virally suppressive ART. Main Outcomes and Measures: Risk of within-couple
HIV transmission to the HIV-negative partner Results: Among 1166 enrolled couples, 888 (mean age, 42
years [IQR, 35-48]; 548 heterosexual [61.7%] and 340 MSM [38.3%]) provided 1238 eligible couple-years of
follow-up (median follow-up, 1.3 years [IQR, 0.8-2.0]). At baseline, couples reported condomless sex for a
median of 2 years (IQR, 0.5-6.3). Condomless sex with other partners was reported by 108 HIV-negative
MSM (33%) and 21 heterosexuals (4%). During follow-up, couples reported condomless sex a median of 37
times per year (IQR, 15-71), with MSM couples reporting approximately 22 000 condomless sex acts and
heterosexuals approximately 36 000. Although 11 HIV-negative partners became HIV-positive (10 MSM;
1 heterosexual; 8 reported condomless sex with other partners), no phylogenetically linked transmissions
occurred over eligible couple-years of follow-up, giving a rate of within-couple HIV transmission of zero,
with an upper 95% confidence limit of 0.30/100 couple-years of follow-up. The upper 95% confidence limit
for condomless anal sex was 0.71 per 100 couple-years of follow-up. Conclusions and Relevance: Among
serodifferent heterosexual and MSM couples in which the HIV-positive partner was using suppressive
ART and who reported condomless sex, during median follow-up of 1.3 years per couple, there were no
documented cases of within-couple HIV transmission (upper 95% confidence limit, 0.30/100 couple-years
of follow-up). Additional longer-term follow-up is necessary to provide more precise estimates of risk.
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IMPORTANCE A key factor in assessing the effectiveness and cost-effectiveness of
antiretroviral therapy (ART) as a prevention strategy is the absolute risk of HIV transmission
through condomless sex with suppressed HIV-1 RNA viral load for both anal and vaginal sex.
OBJECTIVE To evaluate the rate of within-couple HIV transmission (heterosexual andmen
who have sex with men [MSM]) during periods of sex without condoms and when the
HIV-positive partner had HIV-1 RNA load less than 200 copies/mL.
DESIGN, SETTING, AND PARTICIPANTS The prospective, observational PARTNER (Partners of
People on ART—ANew Evaluation of the Risks) study was conducted at 75 clinical sites in 14
European countries and enrolled 1166 HIV serodifferent couples (HIV-positive partner taking
suppressive ART) who reported condomless sex (September 2010 toMay 2014). Eligibility
criteria for inclusion of couple-years of follow-up were condomless sex and HIV-1 RNA load
less than 200 copies/mL. Anonymized phylogenetic analysis compared couples’ HIV-1
polymerase and envelope sequences if an HIV-negative partner became infected to
determine phylogenetically linked transmissions.
EXPOSURES Condomless sexual activity with an HIV-positive partner taking virally
suppressive ART.
MAIN OUTCOMES ANDMEASURES Risk of within-couple HIV transmission to the
HIV-negative partner
RESULTS Among 1166 enrolled couples, 888 (mean age, 42 years [IQR, 35-48]; 548
heterosexual [61.7%] and 340MSM [38.3%]) provided 1238 eligible couple-years of
follow-up (median follow-up, 1.3 years [IQR, 0.8-2.0]). At baseline, couples reported
condomless sex for a median of 2 years (IQR, 0.5-6.3). Condomless sex with other partners
was reported by 108 HIV-negative MSM (33%) and 21 heterosexuals (4%). During follow-up,
couples reported condomless sex a median of 37 times per year (IQR, 15-71), with MSM
couples reporting approximately 22000 condomless sex acts and heterosexuals
approximately 36000. Although 11 HIV-negative partners became HIV-positive (10MSM; 1
heterosexual; 8 reported condomless sex with other partners), no phylogenetically linked
transmissions occurred over eligible couple-years of follow-up, giving a rate of within-couple
HIV transmission of zero, with an upper 95% confidence limit of 0.30/100 couple-years of
follow-up. The upper 95% confidence limit for condomless anal sex was 0.71 per 100
couple-years of follow-up.
CONCLUSIONS AND RELEVANCE Among serodifferent heterosexual andMSMcouples inwhich
theHIV-positive partner was using suppressive ART andwho reported condomless sex, during
median follow-up of 1.3 years per couple, therewere no documented cases of within-couple
HIV transmission (upper 95% confidence limit, 0.30/100 couple-years of follow-up). Additional
longer-term follow-up is necessary to providemore precise estimates of risk.
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S everal studies have demonstrated that HIV-positivepeople takingantiretroviral therapy (ART)whohave lowplasma HIV-1 RNA load have markedly reduced infec-
tiousness for sexual transmission.1-4 In particular, the HPTN
052 study, conducted primarily in heterosexual serodifferent
couples, demonstrated a 96% reduction in HIV transmission
risk inHIV-positive adults randomized to early ART initiation
compared with the group that deferred treatment.4 As a re-
sult, World Health Organization guidelines now recommend
that ART should be offered to all HIV-positive people, irre-
spective of CD4 cell count, to reduce risk of transmission.5
There are, however, a number of gaps in currently avail-
able evidence. The most significant issue is that no data are
available concerning transmission rates for anal sex when
the HIV-positive partner is taking suppressive ART, even
thoughper-act estimates ofHIV transmissibilitywithoutART
are approximately 10 timeshigher for anal intercourse6-9 com-
pared with vaginal sex.10 In addition, in all the transmission
studies in heterosexual couples published to date, including
HPTN 052, most of the observed couple-years of follow-up
have been in the context of reported consistent condom use
(up to 93%),2-4,11-13 which also effectively prevents HIV
transmission.14,15 Study results therefore demonstrate the
added benefit of ART in addition to the use of condoms, not
just from use of ART alone. Condomless sex (sexual activity
in which condoms are not used) was reported for only 330
couple-years of follow-up across all previous studies
combined,2-4,11-13 which is insufficient follow-up to give pre-
cise estimates for transmission in the context of ART alone
when condomsarenot used.14 The absolute risk of sexualHIV
transmission from condomless sex for a person taking stable
suppressive ART therefore remains uncertain.
The primary aim of the PARTNER (Partners of People on
ART—A New Evaluation of the Risks) study was to follow se-
rodifferent partnerships that have penetrative sex without
usingcondoms inwhich theHIV-positivepartner is takingART
withaplasmaHIV-1RNAload less than200copies/mL, tostudy
risk of HIV transmission through anal and vaginal sex in the
absence of condom use.
Methods
Study Design
The PARTNER study was an observational multicenter study
of serodifferent couples, heterosexual andmenwhohave sex
with men (MSM), in which the HIV-positive partner is taking
ART. The methods for the PARTNER study have been
published.16
Ethics Approvals
Prior to the initiationof the studyat each clinical research site,
the protocol, all informed consent forms, and the participant
informationmaterialswere submitted to andapprovedby the
site’s ethics committee (institutional review board or institu-
tionalethicscommittee). In theUnitedKingdom, thestudywas
reviewed and approved by theNorthWest LondonREC2 eth-
ics committee (EC referencenumber 10/H0720/55). Ethics ap-
provalwasobtained in-country for all otherEuropean sites in-
volved in the study. In addition, anyamendments to the study
protocol were submitted and approved by each site’s ethics
committee (institutional review board or ethics committee).
Study Population and Eligibility Criteria
From September 2010, we recruited serodifferent couples
from 75 clinical sites in 14 European countries. HIV-positive
people taking ART and older than 18 years were eligible to
take part with their HIV-negative partners. The HIV-positive
partner was expected to continue taking ART, and the part-
nership met the following criteria: (1) the partners reported
penetrative sex without using condoms (condomless sex)
together in the month before enrollment (during which
period the HIV-negative partner was aware of the HIV status
of the HIV-positive partner) and (2) the partners expected to
have sex together again in the coming months.
Study Procedures
Participating clinics asked HIV-positive patients taking ART
about condomless sexwithHIV-negative partners and if they
wished to take part in an HIV transmission study. If both the
positive and the negative partners agreed to take part, they
signed separate informed consents, which included partner
identification by name. The informed consent also included
explicit reference to the fact thatHIV-negative partners knew
their partner was HIV-positive and that there was a transmis-
sion risk from condomless sex. Clinic staff were asked to rec-
ommend consistent condom use at each study contact.
Follow-upwas stopped if thepartnership ended, thepart-
ners moved away, or either person in the partnership with-
drew consent, but not for changes in sexual behavior or use
ofART(althoughsuchchangescould lead to the follow-uptime
not being eligible for themain analysis). Follow-up in hetero-
sexual couples ended on May 31, 2014, and remains ongoing
forMSMcouples.Follow-up in this reportwascensoredonMay
31, 2014.
Data Collection
Study data were collected on standardized case report forms
after consent at baseline and then every 4 to 6 months. De-
tailed information was collected on sociodemographics (in-
cluding participant self-identified race/ethnicity [using fixed
Key Points
Question What is the risk of HIV transmission through
condomless sex from an HIV-positive person taking suppressive
ART?
Findings In this observational study in HIV-serodifferent
heterosexual andMSM couples having ongoing condomless sex
over 1238 couple-years of follow-up, there were no cases of
within-couple HIV transmission (upper 95% confidence limit of
0.30/100 couple-years of follow-up).
Meaning This study provides estimates of the risk of HIV
transmission through condomless anal and vaginal sex with use of
suppressive ART.
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categories defined by the investigators] to consider a pos-
sibleassociationbetweenrace/ethnicityandtransmissionrate);
self-reported adherence to ART, rated from 0% to 100% over
the previous month (positive partner); sexual activity be-
tween the partners (since last visit), frequency of inter-
course, type of intercourse (receptive or insertive; vaginal or
anal) andwhether ejaculation occurred; sexually transmitted
infections (STIs) and the presence of symptoms suggestive of
an STI; and use of preexposure prophylaxis (PrEP) or postex-
posureprophylaxis (PEP). Injectiondrugusewasassessedand
if needles, syringes, or any part of injection equipment was
shared.
HIV-negativepartnerswerealsoasked if theyhadhadcon-
domless sex with anyone other than their HIV-positive part-
ner since their last visit, the number of other partners, and if
anywereHIV-positive or of unknown serostatus. For theHIV-
positive partner, data onART,CD4cell count, and current and
recent plasma HIV-1 RNA load were recorded through a clini-
cal case report form.
Laboratory Testing and Phylogenetic Analysis
TheHIV-negativepartnerwasasked to test for evidenceofHIV
seroconversion every 6 to 12months.Where possible, a com-
bined antigen/antibody test was used to increase diagnostic
sensitivity in early infection. Plasma HIV-1 RNA was mea-
sured in theHIV-positivepartner according to routine care ev-
ery 6 to 12 months; testing was undertaken at the local diag-
nostic laboratory. If at any time the HIV-negative partner was
found tohavebecomeHIV-positive, a venousblood sample in
EDTA was taken from both partners to determine genetic re-
latedness of HIV-1 pol and env sequences.
Details of the methodology used for sequencing and
analysis are reported in the Supplement. Briefly, following
Sanger sequencing of either plasma HIV-1 RNA or cellular
HIV-1 DNA,17 maximum-likelihood and Bayesian Markov
Chain Monte-Carlo (MCMC) inferences, as implemented in
RAxML-HCP2 v8 and MrBayes v3.2.6, respectively, were
determined as previously described.18 Controls comprised
the 10 closest sequences identified through BLAST searches
ofGenBank (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Replicate
partners’ sequences (obtained fromdifferent sampling points,
different specimentypes,or repeat testingof thesamesample),
andsequencesfromconfirmedHIV-transmissionpairsobtained
in a separate study18 were included as positive controls. A
seroconversioneventwas tobeclassedas linked if thepartners’
sequences grouped together on a monophyletic branch with
high support, defined as a bootstrap value of 0.90 or greater
(maximum likelihood) or a posterior probability of 0.95 or
greater (MCMC), and had a pairwise genetic distance of 0.015
nucleotide substitutions or less per pol site, as per published
methodology.19,20 Sequences showing a genetic distance of
0.045or lessweresubjectedtofurther inspection, toensurethat
potential linkage was notmissed.19,20
Statistical Analysis
The primary analysis was estimation of the rate of transmis-
sion, calculated as the number of HIV infections that oc-
curred during eligible couple-years of follow-up (see defini-
tion below) divided by eligible couple-years of follow-up,
excluding infectionsshowntobephylogeneticallydistinct from
the index patient’s virus (ie, transmission has not been from
the original HIV-positive index partner). Couple-years of
follow-upweredetermined as periods delimited byHIV tests,
and corresponding questionnaires on sexual behavior, in the
HIV-negative partner. Thesewere eligible for inclusion in this
analysis if (1) couples had condomless sex during the period
(reported at the endof the period by theHIV-negative partner
or, if thispartnerdidnot reply,by thepositivepartner); (2) there
was no report of PrEP or PEP use; (3) latest plasmaHIV-1 RNA
load in the positive partner was less than 200 copies/mL and
notdatedolder than 12months; and (4) follow-upoccurredbe-
fore May 31, 2014 (ie, the censoring date).
A sensitivity analysis included periods of follow-up time
in which the HIV-RNA load was suppressed at the beginning
of theperiodbutduringwhich the loadbecameelevated. This
allows inclusion of periods during which a couple may con-
tinuehavingcondomless sexuntil theyknowtheHIVRNAload
is elevated.ExactPoissonmethodswereused tocalculate con-
fidence intervals for the incidence rate of transmission.
The rate ofwithin-couple transmissionwas calculated re-
stricting to couple-years of follow-up during which a certain
type of sex (eg, receptive anal sex with ejaculation) was re-
ported (note that itwasnot required that thiswas theonly type
of sex the couple was having). However, in sensitivity analy-
sis the rate and confidence interval were calculated taking a
hierarchical approach to classifying transmission risk with
types of sex. Having defined such a hierarchy of risk, in refer-
ring to a specific sex act, the upper limit of the rate was esti-
mated if this type of sex was the highest-risk sex being per-
formed. The hierarchy (from highest to lowest risk) was
receptive anal sex with ejaculation, receptive anal sex with-
outejaculation, insertiveanal sex,vaginal sexwithejaculation,
and vaginal sex without ejaculation.
To assesswhether therewere differences in the character-
istics among HIV-negative and HIV-positive people across the
differentgroups (heterosexualmen,heterosexualwomen, and
MSM), the 2-sidedKruskal-Wallis testwasused for continuous
variables and 2-sided χ2 tests for categorical variables.
P < .05 was used as the threshold of statistical signifi-
cance. Missing data were not imputed, and the analysis was
performedonlyontheavailabledata.Datawereanalyzedusing
SAS version 9.3 (SAS Institute Inc).
Sample Size Calculation
In planning the sample size it was known that the transmis-
sion rate was low,3 and the aim was to generate a more pre-
cise estimate of the rate than was available. The sample size
was based on a hypothesized transmission rate of 1 per 1000
couple-years of condomless sex, with the choice of this very
low rate based on arguments laid out in the Swiss
Statement.21 Under this hypothesis, 2000 couple-years of
follow-up were required to have an 85% chance that the
upper limit of the 95% confidence interval for the transmis-
sion rate is less than 0.44 per 100 couple-years of follow-up
(0.2 per 100 couple-years of follow-up, with a transmission
rate of zero). The executive committee stopped follow-up of
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heterosexual couples at May 31, 2014, at the end of phase 1 to
concentrate resources on MSM couples. Phase 2 with MSM
couples only will be continued for a further 4 years to accrue
additional data for anal intercourse. It was prespecified that
further analysis will not be undertaken until the end of the
second phase of the study in 2018.
Results
Eligible Couple-Years of Follow-up Accrued
From the 1166 couples enrolled by May 31, 2014, a total of
1004coupleshadat least 1 follow-upvisit by thecensoringdate
and 888 couples (548 heterosexual and 340 MSM) contrib-
uted 1238 eligible couple-years of follow-up; 1251 when in-
cluding periods of follow-up time inwhich the HIV-RNA load
wassuppressedat thebeginningof theperiodbutduringwhich
the load became elevated. Themain reasons for couples pro-
viding no eligible couple-years of follow-up (n = 116) among
thosewithat least 1 follow-upvisitwerenoHIVtest in thenega-
tive partner (n = 20), use of PEP/PrEP (n = 9), no condomless
sex reported (n = 15), plasma HIV-1 RNA load greater than
200 copies/mL (n = 55), and plasma measurement not avail-
able (n = 17). Participants who contributed eligible couple-
years of follow-up (compared with those who did not) were
slightly older,more likely tohaveundertakenvocational edu-
cation (amongheterosexual participants),more likely tohave
reported sex with other men rather than “other” as HIV ac-
quisitionroute (amongMSM),hadbeenhavingcondomlesssex
for longer (among MSM), and more likely to have a CD4 cell
countgreater than350/mm3(amongheterosexuals) (seeeTable
5 in the Supplement).
Medianeligible years of follow-upper couplewas 1.3 years
(interquartile range [IQR],0.8-2.0).Theestimateddropout rate
was 18per 100couple-years of follow-upwhenconsidering all
the couples enrolled (n = 1166) and 11 per 100 couple-years of
follow-up when restricting to the 888 couples who contrib-
uted toeligible couple-yearsof follow-up.The reason fordrop-
ping out of the study, among couples who contributed eli-
gible couple-yearsof follow-up (888couples)were relationship
broke up (n = 69 [41%]), moved away (n = 15 [9%]), consent
withdrawn/didnotwant to continue (n = 18 [11%]), andother/
not clear (n = 65 [39%]). Among couples contributing eligible
couple-years of follow-up, 340 were MSM, 269 heterosexual
in which the male partner was HIV-positive (male positive/
female negative) and 279 heterosexual in which the female
partnerwasHIV-positive (malenegative/femalepositive).Over-
all, 94% of the eligible couple-years of follow-upwere during
periods of very low plasma HIV-1 RNA load (<50 copies/mL);
the other 6% were during periods with HIV-1 RNA loads be-
tween 50 and 200 copies/mL.
Baseline Couple Characteristics
Characteristics at baseline of the participants who contrib-
utedtoeligiblecouple-yearsof follow-uparereported inTable1.
Median age was 40 to 45 years in all participant groups. HIV-
negativeMSMreportedhavingcondomless sexwith theirposi-
tive partners for a median 1.4 years (IQR, 0.5-3.5 years) prior
toenrollment.Forheterosexual couples thiswas2.8years (IQR,
0.6-7.5 years) for male-negative/female-positive couples and
3.6 years (IQR, 0.7-11.4 years) for male-positive/female-
negative couples.
At baseline, HIV-positive partners had been taking ART a
median of 7.5 years (IQR, 3.3-14.2 years) among heterosexual
women, 10.6 years (IQR, 4.3-15.6 years) among heterosexual
men, and 4.8 years (IQR, 1.9-11.4 years) among MSM. Self-
reported adherence with taking ART was high across all HIV-
positive groups, with 93% of heterosexual men, 94% of het-
erosexualwomen,and97%ofMSMreportinggreater than90%
adherence to ART and very few reporting theymissed taking
ART formore than4consecutivedays, although thiswasmore
common in heterosexual participants (6% men, 8% women)
than inMSM(3%).MSMwere alsomore likely to correctly self-
report a suppressed HIV load (94% of MSM, compared with
84% of heterosexual men and 87% of heterosexual women).
Themajority in all groupshadCD4cell count greater than 350
mm3 at baseline.
Follow-up Clinical and Behavioral Data
During prospective follow-up, 17% of HIV-negative MSM and
18%ofHIV-positiveMSMreportedbeingdiagnosedwithanSTI
at somepoint; amongbothHIV-negative andHIV-positivehet-
erosexualmenandwomen,6%reportedbeingdiagnosedwith
an STI (Table 2).
Thirty-three percent (n = 108) of HIV-negative MSM and
4% of HIV-negative heterosexual men (n = 11) and women
(n = 10) reportedcondomless sexwithotherpartners.Very few
HIV-negative partners reported injecting drugs during
follow-up (3%[n = 10]MSM,2%[n = 5]heterosexualmen, and
1% [n = 2] heterosexual women).
Couples reported frequent condomless sexduring follow-
up, as illustrated by the number of condomless sex acts re-
portedduring follow-up (Table 3). Themediannumberof con-
domless sex acts per year within the partnership reported by
the HIV-negative partner were similar across all groups dur-
ing eligible couple-years of follow-up, with MSM reporting a
median of 42 condomless acts per year (IQR, 18-75) com-
paredwith 35 (IQR, 14-68) for heterosexualmen and 36 (IQR,
13-71) for heterosexual women. Overall, all groups reported
large numbers of condomless sex acts during follow-up, with
morethan22000condomlesssexactsamongMSMand36000
among heterosexual couples.
Data on prevalence of the type of condomless penetra-
tive sex (with the HIV-positive partner) reported by the HIV-
negative partner are shown inFigure 1. By definition, couples
contributing eligible couple-years of follow-up reported con-
domless penetrative sex at some point during follow-up.
Among heterosexual couples, 99% reported vaginal sex with
or without ejaculation and 11.1% reported anal sex. For MSM,
67% of negative partners had receptive anal sex without
ejaculation, 45% had receptive anal sex with their partner
ejaculating inside them, and 92% reported insertive anal sex.
The main reasons reported by HIV-negative partners for
not using a condom were a belief that the risk of HIV trans-
mission was very low (57% heterosexual men, 52% hetero-
sexual women, 63% MSM) and that sex was more enjoyable
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without condoms (38% heterosexual men, 41% heterosexual
women, 61% MSM). Fifteen percent of HIV-negative women
reported not using a condom because they were trying for
a pregnancy.
Rates of HIV Transmission Through Condomless Sex
A total of 11 of the originally HIV-negative partners were ob-
served toacquireHIVduringeligible follow-up, but therewere
nophylogenetically linked transmissions.Of the 11peoplewho
Table 1. Characteristics at Baseline of HIV-Positive and HIV-Negative Partners Enrolled in the PARTNER Study and Eligible for the Primary Analysis
(N = 888 Couples)
Characteristic
HIV-Positive, No. (%)a HIV-Negative, No. (%)a P Valueb
Heterosexual
MSM
(n = 340)
Heterosexual
MSM
(n = 340) HIV-Positive HIV-Negative
Men
(n = 269)
Women
(n = 279)
Men
(n = 279)
Women
(n = 269)
Age, median (IQR) 44.9
(40.1-48.6)
40.1
(34.6-46.5)
41.7
(35.5-46.8)
44.9
(37.6-50.6)
40.3
(34.3-46.7)
40.1
(31.9-46.5)
<.001 <.001
Race/ethnicity
White 221 (83) 170 (62) 305 (91) 229 (85) 217 (82) 301 (89)
<.001 <.001
Black 24 (9) 63 (23) 3 (1) 34 (13) 19 (7) 3 (1)
Asian 4 (2) 27 (10) 9 (3) 1 (<1) 7 (3) 9 (3)
Other 17 (6) 14 (5) 18 (5) 7 (3) 22 (8) 24 (7)
Missing 3 5 5 8 4 3
Education
High school or less 139 (52) 116 (43) 76 (23) 84 (31) 119 (46) 64 (19)
<.001 <.001Vocational education 75 (28) 76 (28) 103 (31) 92 (34) 73 (28) 88 (26)
College or university 51 (19) 77 (29) 156 (47) 93 (35) 69 (26) 183 (55)
Missing 4 10 5 10 8 5
HIV acquisition route
Heterosexual 97 (37) 188 (69) 0
<.001
MSM 22 (8) 1 (<1) 324 (97)
Shared needles or
other injection
equipment
82 (31) 15 (6) 0
Other 64 (24) 67 (25) 10 (3)
Missing 4 8 6
Years of condomless sex,
median (IQR)
3.2
(0.7-11.4)
2.9
(0.8-7.8)
1.5
(0.5-4.1)
2.8
(0.6-7.5)
3.6
(0.7-11.4)
1.4
(0.5-3.5)
<.001 <.001
Missing 26 26 21 25 32 23
Years receiving ART,
median (IQR)
10.6
(4.3-15.6)
7.5
(3.3-14.2)
4.8
(1.9-11.4)
<.001
Missing 31 24 16
Self-reported ART
adherence >90%
Yes 242 (93) 235 (94) 319 (97) .10
Missing 10 29 11
Informed their partner if
they missed doses of ART
No 23 (9) 17 (6) 13 (4)
.002Yes 133 (51) 123 (45) 133 (40)
Did not miss doses 107 (41) 132 (49) 190 (57)
Missing 6 7 4
Self-reported
undetectable HIV load
Yes 220 (84) 231 (87) 309 (94) <.001
Missing 8 12 12
CD4 cell count
>350/mm3
Yes 229 (85) 249 (89) 309 (91) .08
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; MSM, men
who have sex with men.
a Unless indicated there are nomissing values. Percentages are calculated out of
all the participants in that group who contributed to eligible couple-years of
follow-up and provided a response to that question.
bKruskal-Wallis test for continuous variables, χ2 test for categorical variable.
The comparisons are between all of the HIV-positive groups and then between
all of the HIV-negative groups.
HIV Transmission in Serodifferent Couples Using Suppressive ART Original Investigation Research
jama.com (Reprinted) JAMA July 12, 2016 Volume 316, Number 2 175
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/jama/935428/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 02/03/2017
Copyright 2016 American Medical Association. All rights reserved.
became infected, 10 were MSM and 1 was heterosexual; of
these, 8 (73%) reported that they had had recent condomless
sex with others apart from their study partner.
Viral sequences were recovered successfully from all
couples, comprising22of 22 individuals (100%) forpol and20
of 22 individuals (91%) for env. Samples collected from the 2
partners of each couplewere amedianof0months apart (IQR,
0.0-5.9). Thepartnerswhowere initiallyHIV-positivehadsub-
type B infection in all cases. The partners who seroconverted
during the study acquired subtypeB infection in 9 of 11 cases;
1 person (couple 5) acquired subtype A1, and a second person
(couple 6) acquired CRF14_BG (eTable 1 in the Supplement).
In the phylogenetic analyses, none of the partners’ se-
quences clustered together, with consistent results observed
acrossanalyses (Figure2; eFigure 1andeFigure2 in theSupple-
ment). The partners’ sequences showed pairwise genetic dis-
tances consistently greater than 0.040. With couple number
7, the pairwise genetic distances of pol sequenceswere 0.043
Table 2. Characteristics During Follow-up of HIV-Positive and HIV-Negative Partners Eligible for the Primary Analysis (N = 888)
Characteristic
HIV-Positive, No. (%)a HIV-Negative, No. (%)a P Valueb
Heterosexual
MSM
(n = 340)
Heterosexual
MSM
(n = 340) HIV-Positive HIV-Negative
Men
(n = 269)
Women
(n = 279)
Men
(n = 279)
Women
(n = 269)
Years in the study,
median (IQR)
1.9
(1.1-2.4)
1.8
(1.1-2.4)
1.4
(0.8-2.1)
1.8
(1.1-2.4)
1.9
(1.1-2.4)
1.4
(0.8-2.1)
<.001 <.001
STIc 16 (6) 16 (6) 59 (18) 16 (6) 17 (6) 56 (17) <.001 <.001
Gonorrhea 1 (<1) 0 20 (6) 0 0 0 <.001
Warts 2 (1) 5 (2) 8 (2) 8 (3) 0 4 (1) .30
Other STI 2 (1) 12 (4) 0 0 2 (1) 0 <.001 .09
Not specified 12 (5) 1 (<1) 32 (10) 8 (3) 15 (6) 52 (16) <.001 <.001
Missingd 5 3 11 4 6 10
Condomless sex with
other partners, n (%)
11 (4) 10 (4) 108 (33) <.001
Missingd 7 7 12
Condomless sex with
other positive partnerse
9 (3) 0 103 (31) <.001
Condomless sex acts/y,
median (IQR)f
28.2
(10.5-61.3)
30.1
(11.8-60.6)
33.0
(13.0-64.8)
34.6
(13.7-68.3)
35.6
(13.2-70.7)
41.7
(17.6-74.8)
.24 .05
Estimated total
No.condomless sex actsf
15 543 16 945 19 685 18 431 17 509 22 273
Having missed ART
for more than
4 consecutive days
15 (6) 21 (8) 11 (3) .07
Missing 6 11 3
Having injected
nonprescription drugs
7 (3) 10 (4) 18 (5) 5 (2) 2 (1) 10 (3) .21 .14
Missing 5 7 11 5 12 14
Couple-years of
follow-up with reported
frequency of
condomless sex
per monthg
Less than once 90 (24) 87 (21) 76 (17) 97 (23) 72 (19) 68 (15)
.24 .28
1-2 times 59 (16) 65 (15) 63 (14) 70 (17) 64 (17) 70 (16)
3-4 times 54 (14) 85 (20) 80 (18) 76 (18) 72 (19) 88 (20)
5-8 times 93 (24) 95 (23) 103 (24) 105 (25) 93 (24) 121 (27)
More than 8 times 47 (12) 47 (11) 66 (15) 53 (13) 57 (15) 73 (17)
Not reported/missing 37 (10) 39 (9) 50 (11) 18 (4) 23 (6) 18 (4)
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; MSM, men
who have sex with men; STI, sexually transmitted infection.
a Unless indicated there are nomissing values. Percentages are calculated out of
all the participants in that group who contributed to eligible couple-years
of follow-up and provided a response to that question. The comparisons are
between all of the HIV-positive groups and then between all of the
HIV-negative groups.
bKruskal-Wallis test for continuous variables, χ2 test for categorical variable.
c Participants who reported an STI since last visit were asked whether it was
syphilis, gonorrhea, chlamydia, acute genital herpes, chronic genital herpes,
lymphogranuloma venereum, bacterial vaginosis, or other. None reported
being diagnosed with acute genital herpes or syphilis. The following
STIs did not have a frequency above 5 and so were grouped together
as “Other STI”: chlamydia, chronic genital herpes, lymphogranuloma
venereum, bacterial vaginosis, and “other.” Participants who replied “yes” to
the question “Since your last visit, have you had a STI” but did not reply to the
question “If yes, which STI?” were categorized as “not specified.”
dNever replied to this question during follow-up.
e Only people that reported condomless sex with other partners were asked this
question. For this variable “missing” is treated as “no,” and the denominator
used to calculate the percentages is the number of participants who reported
whether they had “[condomless] sex with other partners.”
f Only sex acts within couples are included.
g The denominator is the total group-specific eligible couple-years of follow-up.
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and 0.040 for different sample types; however, there was no
phylogenetic evidence of linked clustering (Figure 2; eFigure
1 and eFigure 2 in the Supplement). Positive control se-
quences showed median genetic distances of 0.004 (IQR,
<0.001-0.008) (eTable 2 in the Supplement) andwere closely
linked onmonophyletic brancheswith bootstrap values 0.98
or greater and posterior probabilities of 1.00.
Given that therewereno linked transmissions (evenwhen
considering periods during which the HIV-RNA load became
elevated [representinga total of 13 couple-yearsof follow-up]),
the estimated rate for transmission through any condomless
sexwith theHIV-positivepartner takingARTwithHIV load less
than 200 copies/mLwas zero, with an upper 95% confidence
limit of 0.30per 100 couple-years of follow-up (0.29when in-
cluding periods of follow-up time inwhich the HIV-RNA load
wassuppressedat thebeginningof theperiodbutduringwhich
the loadbecameelevated). Figure 1 reports the ratesofwithin-
couple HIV transmission per 100 eligible couple-years of
follow-up by sexual behavior reported by the HIV-negative
partner. For all sex in heterosexual couples the upper 95%
Figure 1. Rate of HIV Transmission According to Sexual Behavior Reported by the HIV-Negative Partner
0 86 1210
Rate of Within-Couple Transmission,
per 100 Couple-Years of Follow-up
2 4
HIV-Negative
Members of Eligible
Couples Reporting
Specific Sex Act,
No./Total (%)
All
Couple-Years
of Follow-up
Upper 95%
Confidence
Limit
863/866 (99.7) 1238 0.30Any sex
532/878 (60.6) 629 0.59Vaginal sex
449/849 (52.9) 522 0.71Anal sex
Heterosexual men
272/274 (99.3) 418 0.88Any sex
271/275 (98.5) 383 0.96Vaginal sex
60/264 (22.7) 47 7.85Anal sex
363/862 (42.1) 417 0.88Insertive anal sex
185/864 (21.4) 166 2.23Receptive anal sex with ejaculation
Heterosexual women
261/262 (99.6) 381 0.97Any sex
193/259 (74.5) 246 1.50Vaginal sex with ejaculation
207/257 (80.5) 238 1.55Vaginal sex without ejaculation
61/256 (23.8) 60 6.16Anal sex
Men who have sex with men
330/330 (100) 439 0.84Any sex
328/329 (99.7) 415 0.89Anal sex
303/329 (92.1) 370 1.00Insertive anal sex
60/264 (22.7) 47 7.85Insertive anal sex
148/329 (45.0) 137 2.70Receptive anal sex with ejaculation
217/324 (67.0) 220 1.68Receptive anal sex without ejaculation
37/255 (14.5) 29 12.71Receptive anal sex with ejaculation
55/253 (21.7) 45 8.14Receptive anal sex without ejaculation
Denominators are the group-specific
number of HIV-negative participants
who contributed eligible couple-years
of follow-up. The upper limit of the
95% confidence interval was
estimated using the exact
Poissonmethod.
Table 3. Condomless Sex Acts During Follow-up According to Number of Condomless Sex Acts at Baselinea
No. of Condomless Sex
Acts per 4 Months’ Follow-up
No. of Condomless Sex Acts in The Past 4 mo Reported at Baseline by the HIV-Negative Partner
Total Couple-Years
of Follow-up
1 Time
(n = 41)
2-10 Times
(n = 291)
11-20 Times
(n = 178)
21-40 Times
(n = 163)
>40 Times
(n = 199)
Not Reported
(n = 16)
Less than once 12 (23) 39 (10) 13 (5) 7 (3) 10 (4) 2 (9) 84
1 Time 1 (2) 9 (2) 1 (<1) 2 (1) 0 0 13
2-10 Times 25 (48) 223 (55) 101 (41) 70 (29) 38 (14) 9 (41) 466
11-20 Times 4 (8) 54 (13) 52 (21) 57 (23) 51 (19) 3 (14) 222
21-40 Times 3 (6) 32 (8) 44 (18) 78 (32) 109 (40) 3 (14) 269
>40 Times 1 (2) 3 (1) 6 (2) 13 (5) 35 (13) 0 58
Not reported 6 (12) 41 (10) 29 (12) 17 (7) 29 (11) 4 (18) 126
Total couple-years
of follow-up
52 402 245 245 272 22 1238
a Table reports total number eligible couple-years of follow-up (one of themain
requirements being that condoms are not used) by frequency of condomless
sex acts reported at baseline and during follow-up. Values in parentheses
represent the number of couples reporting a certain frequency at baseline.
The number of couple-years of follow-up have been rounded to the closest
integer; thus, some rows and columns do not sum exactly to the column
or row total.
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confidence limit was 0.97 per 100 couple-years of follow-up
for male-positive/female-negative couples, and 0.88 per
couple-years for female-positive/male-negative couples. In
MSM the upper confidence limit for all sex was 0.84 per 100
couple-years of follow-up. For anal sex, the upper 95% confi-
dence limit was 0.71 per 100 couple-years of follow-up (het-
erosexual andMSMdata combined), and for receptive anal sex
with ejaculation itwas 2.23 per 100 couple-years of follow-up
(heterosexual and MSM data combined) and 2.70 per 100
couple-years of follow-up (MSM only). The upper limit of the
95% CI was higher for anal sex owing to the lower number of
couple-years of follow-up accrued to date.
When considering a hierarchical approach (ie, the act-
specific rates were restricted to couple-years of follow-up in
which that type of act was the highest-risk type of sex re-
ported), the upper 95% confidence limit was higher: for re-
ceptive anal sex without ejaculation, the upper limit in-
creased from 8.14 to 11.95 per 100 couple-years of follow-up
forheterosexualwomenand from1.68 to3.06per 100couple-
years of follow-up forMSM; for vaginal sex, theupper limit in-
creased from 0.59 to 0.69 per 100 couple-years of follow-up
(heterosexual men and women combined) (eTable 4 in the
Supplement). A table detailing the rates and upper 95% con-
fidence limits using this approach has been included in the
Figure 2. Phylogenetic Tree of Pol Sequences From9 CouplesWith Subtype B Infection
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Bayesian Markov Chain Monte-Carlo (MCMC) inference (012212+I+G+F model).
Branch line weight is proportional to the posterior probability. Partners’
sequences are in blue; N indicates the initially HIV-negative partner, whereas
P indicates the initially HIV-positive partner. Control sequences comprised the
10 closest sequences identified through BLAST searches of GenBank. Positive
control sequences comprised replicate sequences from study partners (in red)
and sequences from confirmed transmission pairs obtained in a separate study
(in orange).19
a Sequences 9N2 and 9N3were obtained from the same sample in 2 separate
experiments.
Research Original Investigation HIV Transmission in Serodifferent Couples Using Suppressive ART
178 JAMA July 12, 2016 Volume 316, Number 2 (Reprinted) jama.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/jama/935428/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 02/03/2017
Copyright 2016 American Medical Association. All rights reserved.
supplementarymaterial (eTable 4 in the Supplement). All but
3nonlinkedHIV-1 infections occurred amongpartners report-
ing condomless sex with other partners.
Discussion
This studyprovides the first estimate toour knowledgeofHIV
transmission risk through condomless anal sex in which the
HIV-positivepartner is takingARTwithsuppressedplasmaHIV
viral load and also provides an estimate of the absolute rate
ofHIVtransmissionthroughcondomlessheterosexual sex.The
estimate of the overall transmission rate, and the transmis-
sion rate for anal sex,was zero.However, 95%confidence lim-
its suggest that with eligible couple-years accrued so far, ap-
preciable levelsof riskcannotbeexcluded,particularly foranal
sex and when considered from the perspective of a cumula-
tive risk over several years.
Only couples that continued to have condomless sexwere
included in this study, to enable focus on situations in which
transmission risk without ART is highest. This contrasts with
other transmission studies, including HPTN 052, in which re-
ported condomusewas high (93%)4 and the low absolute rate
of transmission in the ART group reflects both ART and con-
dom use, thus assessing 2 prevention strategies in combina-
tion, not just ART alone. It is important to know how low
the risk of transmissionwaswith theuse ofARTalonewithout
simultaneous use of condoms, and this study contains more
than 3 times the couple-years of follow-up for condomless
sexthanall theotherpreviousstudiescombined, includingmore
than 500 couple-years of follow-up of condomless anal sex.14
BothMSMandheterosexualcouples inthisstudyreportedregu-
larly having sexwithout a condomduring follow-up. Based on
the number and type of sex acts and the cumulative probabil-
ity of HIV transmission, more than 100 transmissions would
have been expected in theMSMgroup alone (see Supplement)
if the HIV-positive partner had not been taking ART.10
Although these results cannot directly provide an answer
to the question of whether it is safe for serodifferent couples
to practice condomless sex, this study provides informative
data (especially forheterosexuals) for couples tobase theirper-
sonal acceptability of risk on. In the absence of ART, recep-
tiveanal sexwithejaculation is recognizedas carryingahigher
risk than other forms and, despite an observed transmission
rate of zero for this risk behavior, a clinically important rate
of less than 2.2 per 100 couple-years of follow-up cannot be
excluded. This translates into an upper limit estimate of 20%
risk over 10 years. Because the upper limit of the 95% confi-
dence interval is a function of the amount of couple-years of
follow-up for that sexual act, additional follow-up in MSM is
therefore needed through the second phase of the PARTNER
study (PARTNER2) toprovidemorepreciseestimates for trans-
mission risk in MSM in the context of ART. These data are
needed toprovideequalityof evidencebetweenMSMandhet-
erosexual couples, to inform both policy and also individual
choice on condom use.
Althoughno linkedHIVtransmissionswithincoupleswere
detected, 11 unlinked HIV transmissions occurred during eli-
gible follow-up. One-third of HIV-negativeMSM in this study
reportedhaving condomless sex concurrentlywithotherpart-
nersoutside themain relationship.Ahighprevalenceof sexual
concurrencyand inparticular concurrent condomless anal sex
hasbeen reported inother studies inMSM.22,23Related to this,
HIV-negativeMSMwere also relatively commonly diagnosed
with an STI. Acquisition of an STIwasnot associatedwith risk
of HIV-1 transmission within the couples under study, al-
though power was limited to exclude a possible true effect.
This study has several limitations. The original design
aimedtoobserve2000couple-yearsof follow-up,butonly1238
couple-years were eligible for the primary analysis. Because
the primary analysis involves the estimation of a rate with a
95%confidence interval, this doesnot substantially affect the
interpretation. In addition, although therewas amoderatede-
gree of dropout of studyparticipants, the reasons for dropout
do not suggest that thosewho dropped outwould have expe-
rienced a higher transmission rate while virally suppressed
when taking ART. The follow-up timewas relatively short, al-
thoughat studyentrycouples reportedhavingcondomless sex
with their current partner for several months to years. Direct
evidence that some individuals are particularly susceptible to
early acquisitionofHIV infection is currently lacking, but it re-
mains possible that the transmission rate is higher in the ini-
tial period of condomless sex between a couple.Moreover, al-
though the transmission rate was also zero in the 23% of
couples in the study in which the partnership was relatively
recent (< 6months), the risk of HIV transmission in very new
partnerships could not be determined.
Conclusions
Among serodifferent heterosexual andMSMcouples inwhich
theHIV-positive partner was using suppressive ART andwho
reportedcondomless sex,duringmedian follow-upof 1.3years
per couple, there were no documented cases of within-
coupleHIVtransmission(upper95%confidence limit,0.30/100
couple-years of follow-up). Additional longer-term follow-up
is necessary to provide more precise estimates of risk.
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